Retinoblastoma
Drug research and approvals for retinoblastoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 22 studies of retinoblastoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 0 approved and 8 open orphan designations naming it.
- Recruiting worldwide: 22
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 0
- A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable…NCT07633756 · Phase 1 · M.D. Anderson Cancer Center · starts Oct 19, 2026
- High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous SeedNCT06972602 · Early Phase 1 · Eye & ENT Hospital of Fudan University · starts Apr 1, 2025
- Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary…NCT06725173 · Not reported · University of Washington · starts Mar 16, 2026
- Retinoblastoma Phase II Expanded Access Clinical TrialNCT06679634 · Phase 2 · Targeted Therapy Technologies, LLC · starts Feb 21, 2025
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft…NCT06498648 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Mar 18, 2026
- Targeting NUDT21 siRNA Drugs for Patients With Refractory RetinoblastomaNCT06424301 · Early Phase 1 · Eye & ENT Hospital of Fudan University · starts Dec 20, 2024
- Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLCNCT06369181 · Not reported · Fudan University · starts Jan 1, 2021
- Trilateral Retinoblastoma: Incidence and OutcomesNCT06367530 · Not reported · Amsterdam UMC, location VUmc · starts Jan 1, 2024
- A Study to Give Treatment Inside the Eye to Treat RetinoblastomaNCT05504291 · Phase 2 · Children's Oncology Group · starts Nov 4, 2022
Phase 3 8
- CarboplatinDNA inhibitor
- TopotecanDNA topoisomerase I inhibitor
- VincristineTubulin inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- CyclophosphamideDNA inhibitor
- ThiotepaDNA inhibitor
- CisplatinDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
Phase 2 6
- 2-mercaptoethanesulfonic acid
- CyclosporineCyclophilin A modulator
- TemozolomideDNA inhibitor
- RanibizumabVascular endothelial growth factor A inhibitor
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- ConberceptVascular endothelial growth factor A inhibitor
Phase 1 or earlier 2
- BusulfanDNA inhibitor
- AmifostineReactive metabolite scavenging agent
How its trials ended
121 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 23 whose ending is known, 13% met their primary endpoint, 0% missed it and 87% stopped early.
- Completed, result not reported4638%
- Ongoing3630%
- Status unknown1613%
- Stopped: enrollment or feasibility97%
- Stopped: other or unclear87%
- Met its primary endpoint32%
- Stopped: sponsor or business decision22%
- Stopped: lack of efficacy11%
| Dec 9, 2022 | Intravitreal melphalan for intraocular retinoblastomaMelphalan / Etoposide phosphate | Childrens Oncology Group | Ongoing |
| Oct 15, 2020 | A phase I study of sequestered transscleral, controlled-release topotecan delivered from an episcleral reservoir in unilateral group d retinoblastoma eyesEpiscleral topotecan | Targeted Therapy Technologies, LLC | Pending |
| Apr 22, 2020 | Phase I sustained-release topotecan episcleral plaque (chemoplaque) for retinoblastoma (step-rb)Topotecan | The Hospital for Sick Children | Closed |
| Jul 24, 2025 | MelphalanTreatment of retinoblastoma | Zhaoke Ophthalmology | Designated |
| Jul 29, 2024 | TopotecanTreatment of retinoblastoma | Lumentra Therapeutics Inc. | Designated |
| Feb 7, 2022 | Genetically modified human adenovirus encoding human PH20Treatment of Retinoblastoma | VCN Biosciences S.L. | Designated |
| Nov 24, 2020 | Murine double minute-2 (MDM2) or Human double minute-2…Treatment of Retinoblastoma | Ascentage Pharma Group Inc. | Designated |
| Sep 14, 2020 | N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-tr…Treatment of retinoblastoma | Oxular Ltd | Designated |
| Jul 24, 2019 | Episcleral TopotecanTreatment of retinoblastoma | Targeted Therapy Technologies, LLC., DBA: 3T Ophthalmics | Designated |
| Nov 17, 2015 | ThioureidobutyronitrileTreatment of retinoblastoma. | Innovation Pharmaceuticals, Inc. | Designated |
| Nov 19, 2012 | MelphalanTreatment of retinoblastoma | EyePoint Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA